Some of the Top Pharmaceutical Companies to Watch in New Year 2021
“Glioblastoma is the most common and aggressive cancerous brain tumour in adults due to its resistance to therapy. Treatment usually involves surgery, followed by chemotherapy and radiation therapy. Despite these intensive efforts, in most cases tumour cells regrow after treatment and the cancer recurs,” reports Science Daily. However, there may be a treatment option with the development of Berubicin, an anthracycline anticancer drug used for the treatment of malignant gliomas, as noted by Targeted Oncology.
As reported by Grand Review Research, “According to U.S. National Cancer Institute GBM is considered as the most aggressive form of brain cancer which represents 15.4% of all primary brain tumors and about 60% - 75% of all astrocytoma and shows rapid growth rate of benign cells in the organ. Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022.” That could open a world of opportunity for companies such as